Endothelial function as a determinant of vascular function and structure: A new therapeutic target

American Journal of Cardiology

Volumn 79, Issue 5 A, 1997, Pages 3-8

  Gibbons, Gary H ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; NITRIC OXIDE;

ATHEROSCLEROSIS; BLOOD VESSEL TONE; CELL PROLIFERATION; CONFERENCE PAPER; ENDOTHELIUM CELL; HEART FAILURE; HEART VENTRICLE REMODELING; HEMOSTASIS; HUMAN; HUMAN CELL; HYPERTENSION; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; STRUCTURE ACTIVITY RELATION;

EID: 0030954149     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(97)00122-7     Document Type: Conference Paper

References (25)

1. Gibbons GH, Dzau VJ. The emerging concept of vascular remodeling. N Engl J Med 1994;330:1431-1438.
2. Rubanyi GM. The role of endothelium in cardiovascular homeostasis and diseases. J Cardiovasc Pharmacol 1993;22(suppl 4):S1-S14.
3. Laragh JH. The renin system and the impact of ACE inhibition for understanding, diagnosis, and treatment of hypertension. In: Sonnenblick EH, Laragh JH, Lesch M, eds. New Frontiers in Cardiovascular Therapy: Focus on Angiotensin Converting Enzyme Inhibition. Princeton, NJ: Excerpta Medica, 1989:83-116.
4. Weber MA, Neutel JM, Smith DHG. Circulatory and extracirculatory effects of angiotensin-converting enzyme inhibition. Am Heart J 1992;123:1414-1420.
5. Unger T, Ganten D, Lang RE, Schölkens BA. Is tissue converting enzyme inhibition a determinant of the antihypertensive efficacy of converting enzyme inhibitors? Studies with the two different compounds, HOE498 and MK421, in spontaneously hypertensive rats. J Cardiovasc Pharmacol 1984;6:872-880.
6. Dzau VJ. Angiotensin-converting enzyme as a multimechanistic factor in CAD. J Myocard Ischemia 1995;7(suppl 1):6-14.
7. Morishita R, Gibbons GH, Ellison KE, Lee W, Zhang L, Yu H, Kaneda Y, Ogihara T, Dzau VJ. Evidence for direct local effect of angiotensin in vascular hypertrophy. In vivo gene transfer of angiotensin converting enzyme. J Clin Invest 1994;94:978-984.
8. Ohno M, Gibbons GH, Dzau VJ, Cooke JP. Shear stress elevates endothelial cGMP: role of a potassium channel and G-protein coupling. Circulation 1993;88:193-197.
9. Nishida K, Harrison DG, Navas JP, Fisher AA, Dockery SP, Uematsu M, Nerem RM, Alexander RW, Murphy TJ. Molecular cloning and characterization of the constitutive bovine aortic endothelial cell nitric oxide synthase. J Clin Invest 1992;90:2092-2096.
10. Davies PF. Flow-mediated endothelial mechanotransduction. Physiol Rev 1995;75:519-560.
11. Tronc F, Wassef M, Esposito B, Tedgui A. Role of nitric oxide in blood flow-induced vascular remodeling. (Abstr.) Circulation 1995;92(suppl 1):1-561.
12. Kramsch DM, Aspen AJ, Abramowitz BM, Kreimendahl T, Hood WB Jr. Reduction of coronary atherosclerosis by moderate conditioning exercise in monkeys on an atherogenic diet. N Engl J Med 1981;305:1483-1489.
13. Sessa WC, Pritchard K, Seyedi N, Wang J, Hintze TH. Chronic exercise in dogs increases coronary vascular nitric oxide production and endothelial cell nitric oxide synthase gene expression. Circ Res 1994;74:349-353.
14. von der Leyen HE, Gibbons GH, Morishita R, Lewis NP, Zhang L, Nakajima M, Kaneda Y, Cooke JP, Dzau VJ. Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene. Proc Natl Acad Sci USA 1995;92:1137-1141.
15. Marks DS, Vita JA, Folts JD, Keaney JF Jr, Welch GN, Loscalzo J. Inhibition of neointimal proliferation in rabbits after vascular injury by a single treatment with a protein adduct of nitric oxide. J Clin Invest 1995;96:2630-2638.
16. De Caterina R, Libby P, Peng HB, Thannickal VJ, Rajavashisth TB, Gimbrone MA Jr, Shin WS, Liao JR. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest 1995;96:60-68.
17. Peng HB, Libby P, Liao JK. Induction and stabilization of I kappa B alpha by nitric oxide mediates inhibition of NF-kappa B. J Biol Chem 1995;270:14214-14219.
18. Haskell WL, Sims C, Myll J, Bortz WM, St Goar FG, Alderman EL. Coronary artery size and dilating capacity in ultradistance runners. Circulation 1993;87:1076-1082.
19. Kitazono T, Padgett RC, Armstrong ML, Tompkins PK, Heistad DD. Evidence that angiotensin II is present in human monocytes. Circulation 1995;91:1129-1134.
20. Rajagopalan S, Kurz S, Münzel T, Tarpey M, Freeman BA, Griendling KK, Harrison DG. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 1996;97:1916-1923.
21. Shah PK, Falk E, Badimon JJ, Fernandez-Ortiz A, Mailhac A, Villareal-Levy G, Fallon JT, Regnstrom J, Fuster V. Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation 1995;92:1565-1569.
22. Rajagopalan S, Meng SXP, Ramasamy S, Harrison DG, Galis Z. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro: implications for atherosclerotic plaque stability. J Clin Invest 1996;98:2572-2579.
23. Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ, Brown MJ. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996;347:781-786.
24. Finta KM, Fischer MJ, Lee L, Gordon D, Pitt B, Webb RC. Ramipril prevents impaired endothelium-dependent relaxation in arteries from rabbits fed an atherogenic diet. Atherosclerosis 1993;100:149-156.
25. Chobanian AV, Haudenschild CC, Nickerson C, Drago R. Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit. Hypertension 1990;15:327-331.